MedTrace Logo

Does a Migraine Medication Decrease Rotational Motion Sickness in People Suffering From Migraines?

NCT00360282 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2014-12-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if Rizatriptan, a migraine medication, lowers motion sickness in migraine sufferers.

Conditions

Interventions

DRUG

Rizatriptan

10 mg Rizatriptan in an unlabeled pill given once on one of two visits

OTHER

Placebo

In an unlabeled pill given once on one of two visits.

Sponsors & Collaborators

Principal Investigators

  • Joseph M Furman, MD, PhD · University of Pittsburgh

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-31
Primary Completion
2009-01-31
Completion
2010-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00360282 on ClinicalTrials.gov